Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LP-168 |
Synonyms | |
Therapy Description |
LP-168 is a selective BTK inhibitor with activity against wild-type BTK and BTK C481S, potentially inducing cytotoxicity in tumor cells and leading to antitumor activity (Blood (2023) 142 (Supplement 1): 416, Blood (2023) 142 (Supplement 1): 4400). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LP-168 | LP168|LP 168 | BTK inhibitor 37 | LP-168 is a selective BTK inhibitor with activity against wild-type BTK and BTK C481S, potentially inducing cytotoxicity in tumor cells and leading to antitumor activity (Blood (2023) 142 (Supplement 1): 416, Blood (2023) 142 (Supplement 1): 4400). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |